Dr. André Habel starts at GeneQuine as Head of Manufacturing [ 14 Oct 2013 ]

The seasoned expert in GMP manufacturing of viral agents, Dr. André Habel, is GeneQuine's newest addition to the management team.

He will be responsible for the development of a robust, scalable GMP manufacturing platform for GeneQuine's gene therapy vectors.

Dr. Habel has more than 10 years experience in GMP manufacturing of viral agents. Prior to joining GeneQuine, he co-founded and was Chief Technology Officer of Themis Bioscience, an Austrian-based biotechnology company specialized in the development of vaccines against emerging viral diseases. Prior to this, Dr. Habel gained experience in production and formulation of biopharmaceuticals and viral vaccines at Intercell AG (now Valneva SE), Austria, Intercell Biomedical (now Valneva SE), Scotland, Berna Biotech (now Crucell NV), Switzerland and Stabilitech Ltd, London.

Before starting his corporate career, Dr. Habel spent more than 5 years at the Institut Pasteur, France, were he was trained in molecular virology.

Back